Back to Journals » Therapeutics and Clinical Risk Management » Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2328)
- Volume 20, 2024 (20)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Journal Articles:
Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications
Lymphoproliferation, clinically expressed with lymphadenopathies, hepato-splenomegaly, or lymphoid organ infiltration, is a common feature of different diseases, ranging from infections to hematologic malignancies. In the recent years, there has also been an increasing interest in the impact of lymphoproliferative features in patients with inborn errors of immunity (IEI), as benign polyclonal lymphoproliferation is one of the leading signs in different IEIs, including the autoimmune lymphoproliferative syndrome and other immune dysregulation disorders. Moreover, the knowledge on lymphoproliferative malignancies israpidly progressing, with the increasing availability of new therapeutic regimens.